Laura Folgori

Laura Folgori

Auto-generated profile, based on publicly available information

Laura Folgori

Paediatric Infectious Disease Unit Department of Pediatrics Luigi Sacco Hospital University of Milan Milan Italy

Research Focus & Metrics

Academic Career Length

10Years (2017-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 March 2018 in Clinical Microbiology and Infection
Verified
Journal Article
Closed access
LFL. Folgori
L. Folgori
CTC. Tersigni
C. Tersigni
YHY. Hsia
Y. Hsia
CKC. Kortsalioudaki
C. Kortsalioudaki
PHP. Heath
P. Heath
JBJ. Bielicki
J. Bielicki

1 November 2017 in The Lancet Global Health
Verified
Journal Article
Open access
LFLaura Folgori
Laura Folgori
SESally J Ellis
Sally J Ellis
JBJulia A Bielicki
Julia A Bielicki
PHPaul T Heath
Paul T Heath
MSMike Sharland
Mike Sharland
MBManica Balasegaram
Manica Balasegaram

7 December 2017 in Drugs
Verified
Journal Article
Closed access
PDF file
PPPaola Pansa
Paola Pansa
YHYingfen Hsia
Yingfen Hsia
JBJulia Bielicki
Julia Bielicki
ILIrja Lutsar
Irja Lutsar
AWA. Sarah Walker
A. Sarah Walker
LFLaura Folgori
Laura Folgori

31 December 2019 in BMJ Open
Verified
Journal Article
Open access
PDF file
LFLaura Folgori
Laura Folgori
ILIrja Lutsar
Irja Lutsar
JSJoseph F Standing
Joseph F Standing
AWA Sarah Walker
A Sarah Walker
EREmmanuel Roilides
Emmanuel Roilides
MSMike Sharland
Mike Sharland
Antimicrobial development for children remains challenging due to multiple barriers to conducting randomised clinical trials (CTs). There is currently considerable heterogeneity in the design and conduct of paediatric antibiotic studies, hampering comparison and meta-analytic approaches. The board of the European networks for paediatric research at the European Medicines Agency (EMA), in collaboration with the Paediatric European Network for Treatments of AIDS—Infectious Diseases network (www.penta-id.org), recently developed a Working Group on paediatric antibiotic CT design, involving academic, regulatory and industry representatives. The evidence base for any specific criteria for the design and conduct of efficacy and safety antibiotic trials for children is very limited and will evolve over time as further studies are conducted. The suggestions being put forward here are based on the adult EMA guidance, adapted for neonates and children. In particular, this document provides suggested guidance on the general principles of harmonisation between regulatory and strategic trials, including (1) standardised key inclusion/exclusion criteria and widely applicable outcome measures for specific clinical infectious syndromes (CIS) to be used in CTs on efficacy of antibiotic in children; (2) key components of safety that should be reported in paediatric antibiotic CTs; (3) standardised sample sizes for safety studies. Summarising views from a range of key stakeholders, specific criteria for the design and conduct of efficacy and safety antibiotic trials in specific CIS for children have been suggested. The recommended criteria are intended to be applicable to both regulatory and clinical investigator-led strategic trials and could be the basis for harmonisation in the design and conduct of CTs on antibiotics in children. The next step is further discussion internationally with investigators, paediatric CTs networks and regulators.

3 February 2020 in Pediatric Allergy and Immunology
Verified
Journal Article
Open access
PDF file
MSMarco Ugo Andrea Sartorio
Marco Ugo Andrea Sartorio
LFLaura Folgori
Laura Folgori
Gianvincenzo ZuccottiGianvincenzo Zuccotti
Gianvincenzo Zuccotti
Chiara MameliChiara Mameli
Chiara Mameli
Rotavirus (RV) disease is a leading cause of mortality and morbidity, especially in children under 5 years of age. The introduction of the two oral rotavirus vaccines Rotarix® and RotaTeq® has shown significant reductions in RV‐related mortality, severe RV disease, and hospitalizations. However, some barriers, including a reduced efficacy in low‐income countries, safety issues regarding the intussusception risk, age restrictions on vaccine use, the live‐attenuated nature itself, and the substantial vaccine costs, currently restrict the full potential of RV disease prevention. Therefore, research is now focusing on the implementation of new oral vaccines and the development of parenteral vaccines to overcome these limits. This review provides an overview of the new rotavirus vaccines in clinical development and the ongoing clinical trials on new RV vaccines in the pediatric age.